Abstract:Background and Purpose-Oligodendrogenesis is essential for white matter repair after stroke. Although agonists of peroxisome proliferator-activated receptors. confer neuroprotection in models of cerebral ischemia, it is not known whether this effect extends to white matter protection. This study tested the hypothesis that the peroxisome proliferator-activated receptors. agonist rosiglitazone enhances oligodendrogenesis and improves long-term white matter integrity after ischemia/reperfusion.Methods-Male adult C57/BL6 mice (25-30 g) were subjected to 60-minute middle cerebral artery occlusion and reperfusion. Rosiglitazone (3 mg/kg) was injected intraperitoneally once daily for 14 days beginning 2 hours after reperfusion. Sensorimotor and cognitive functions were evaluated <= 21 days after middle cerebral artery occlusion. Immunostaining was used to assess infarct volume, myelin loss, and microglial activation. Bromodeoxyuridine (BrdU) was injected for measurements of proliferating NG2(+) oligodendrocyte precursor cells (OPCs) and newly generated adenomatous polyposis coli(+) oligodendrocytes. Mixed glial cultures were used to confirm the effect of rosiglitazone on oligodendrocyte differentiation and microglial polarization.Results-Rosiglitazone significantly reduced brain tissue loss, ameliorated white matter injury, and improved sensorimotor and cognitive functions for at least 21 days after middle cerebral artery occlusion. Rosiglitazone enhanced OPC proliferation and increased the numbers of newly generated mature oligodendrocytes after middle cerebral artery occlusion. Rosiglitazone treatment also reduced the numbers of Iba1(+)/CD16(+) M1 microglia and increased the numbers of Iba1(+)/CD206(+) M2 microglia after stroke. Glial culture experiments confirmed that rosiglitazone promoted oligodendrocyte differentiation, perhaps by promoting microglial M2 polarization.Conclusions-Rosiglitazone treatment improves long-term white matter integrity after cerebral ischemia, at least, in part, by promoting oligodendrogenesis and facilitating microglial polarization toward the beneficial M2 phenotype.

Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.

Rosiglitazone Attenuates Hyperglycemia-Enhanced Hemorrhagic Transformation after Transient Focal Ischemia in Rats.

Rosiglitazone Via Upregulation of Akt/Enos Pathways Attenuates Dysfunction of Endothelial Progenitor Cells, Induced by Advanced Glycation End Products

Rosiglitazone Promotes White Matter Integrity And Long-Term Functional Recovery After Focal Cerebral Ischemia

Rosiglitazone ameliorates the dysfunction of endothelial progenitor cells induced by advanced glycation end products

Peroxisome Proliferator-Activated Receptor Γ Agonist Rosiglitazone Protects Blood–Brain Barrier Integrity Following Diffuse Axonal Injury by Decreasing the Levels of Inflammatory Mediators Through a Caveolin-1-Dependent Pathway

Cardioprotective effects of acute rosiglitazone treatment

Effects of Rosiglitazone on Serum Levels of Lipids and Inflammatory Factors in Atherosclerotic Rats

Polarization of Microglia to the M2 Phenotype in A Peroxisome Proliferator-Activated Receptor Gamma-Dependent Manner Attenuates Axonal Injury Induced by Traumatic Brain Injury in Mice

Rosiglitazone attenuates endothelial progenitor cell apoptosis induced by TNF-α via ERK/MAPK and NF-κB signal pathways.

Rosiglitazone Ameliorates Tissue Plasminogen Activator‐induced Brain Hemorrhage after Stroke

Rosiglitazone regulates astrocyte polarization and neuroinflammation in a PPAR-γ dependent manner after experimental traumatic brain injury

Rosiglitazone Attenuates Cell Apoptosis Through Antioxidative and Anti-Apoptotic Pathways in the Hippocampi of Spontaneously Hypertensive Rats.

Rosiglitazone attenuates early brain injury after experimental subarachnoid hemorrhage in rats

Rosiglitazone Ameliorates Diffuse Axonal Injury by Reducing Loss of Tau and Up-Regulating Caveolin-1 Expression

Rosiglitazone attenuates hypoxia-induced renal cell apoptosis by inhibiting NF-κB signaling pathway in a PPARγ-dependent manner

Peroxisome Proliferator–activated Receptor-Γ Agonist Rosiglitazone Reduces Clinical Inflammatory Responses in Type 2 Diabetes with Coronary Artery Disease after Coronary Angioplasty

Inhibitory Effects of Rosiglitazone on Lipopolysaccharide-Induced Inflammation in a Murine Model and HK-2 Cells

Rosiglitazone Polarizes Microglia and Protects Against Pilocarpine-Induced Status Epilepticus.

The Role of Rosiglitazone in the Proliferation of Vascular Smooth Muscle Cells after Experimental Subarachnoid Hemorrhage

Effects of peroxisome proliferator activated receptor γ Pioglitazone on cerebral ischemic injury in rats